Evaluation of the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin administered as sham, postexposure prophylaxis of tetanus.

Antimicrobial Agents and Chemotherapy
R ForratJ Lang

Abstract

In a monocentric, double-blind, randomized trial, we examined the safety and pharmacokinetic profile of a new, pasteurized, human tetanus immunoglobulin (P-HTIG). As part of the purification process, P-HTIG has undergone a heat treatment step (10 h at 60 degrees C) and the removal of Merthiolate. Forty-eight adults with a history of tetanus vaccination were randomized into four groups (n = 12 per group) to receive one of two different batches of this P-HTIG simultaneously with either tetanus-diphtheria (Td) vaccine (sham, postexposure prophylaxis of tetanus) or placebo. Local reactions at the injection site were followed for the first 3 days after injection, and systemic reactions were followed during the entire study period, i.e., up to 42 days posttreatment. Blood samples for tetanus antibody titer determination (enzyme-linked immunosorbent assay method) were drawn prior to treatment on day 0 and on days 1, 2, 3, 7, 14, 21, 28, 35, and 42. A normalization of tetanus antibody titers (subtraction of the day 0 value for each subject at each time period) was performed to assess the additive effect of P-HTIG on tetanus antibody titers. The pharmacokinetic parameters were determined by both a compartmental analysis (modelization) a...Continue Reading

References

Jan 1, 1975·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·K Ullberg-Olsson
Jan 1, 1992·Vaccine·J D PorterN T Begg
May 1, 1989·The Journal of International Medical Research·A W HarcusK A Bryett
Jan 1, 1988·European Journal of Clinical Pharmacology·J K AronsonF Follath
Apr 1, 1988·Contact Dermatitis·N H Cox, A Forsyth
Feb 26, 1994·BMJ : British Medical Journal·E MillerL Hindle
Dec 1, 1961·The Journal of Pediatrics·J SMOLENSJ STOKES
Jan 23, 1964·The New England Journal of Medicine·J A MCCOMB

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.